Romiplostim
Thrombopoietin Receptor Agonist — BLOOD AND BLOOD FORMING ORGANS
Also known as: AMG-531, AMG531, nplate
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Romiplostim is a drug in the Thrombopoietin Receptor Agonist class catalogued in DrugCentral. It was first approved by the FDA in 2008. Its mechanism of action is classified as Thrombopoietin Receptor Agonists. DrugCentral lists 1 molecular target, including MPL. Recorded indications include Aplastic anemia and Chronic idiopathic thrombocytopenic purpura.
- Drug class: Thrombopoietin Receptor Agonist.
- Mechanism of action: Thrombopoietin Receptor Agonists.
- Molecular targets: MPL (1 listed in DrugCentral).
- Indications: Aplastic anemia and Chronic idiopathic thrombocytopenic purpura.
- ATC code: B02BX04 (Other systemic hemostatics).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Aplastic anemia
- Chronic idiopathic thrombocytopenic purpura
Mechanism & targets
| Mechanism of action (MoA) | Thrombopoietin Receptor Agonists |
|---|---|
| Established pharmacologic class | Thrombopoietin Receptor Agonist |
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Thrombopoietin receptor | MPL | agonist | — |
Regulatory approvals (3)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2011-01-21 | PMDA | — | Kyowa Hakko Kirin | Yes |
| 2009-02-04 | EMA | — | — | |
| 2008-08-22 | FDA | — | AMGEN |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
B02BX04 | BLOOD AND BLOOD FORMING ORGANS › ANTIHEMORRHAGICS › VITAMIN K AND OTHER HEMOSTATICS › Other systemic hemostatics |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Platelet count abnormal | 3355.8 |
| Platelet count decreased | 2627.3 |
| Therapeutic response decreased | 2040.0 |
| Thrombocytopenia | 944.3 |
| Thrombocytosis | 885.8 |
| Platelet count increased | 802.9 |
| Drug ineffective | 733.9 |
| Bone marrow reticulin fibrosis | 613.0 |
| Myelofibrosis | 525.1 |
| Splenectomy | 512.5 |
| Death | 510.3 |
| Petechiae | 507.9 |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | 267639-76-9 |
| InChIKey | — |
| PubChem CID | 135449332 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Romiplostim used for?
DrugCentral lists the following indications for Romiplostim: Aplastic anemia and Chronic idiopathic thrombocytopenic purpura.
How does Romiplostim work?
Romiplostim is classified as Thrombopoietin Receptor Agonists; its molecular targets in DrugCentral include MPL (agonist).
When was Romiplostim first approved?
Romiplostim was first approved by the FDA in 2008.
What drug class does Romiplostim belong to?
Romiplostim is in the Thrombopoietin Receptor Agonist class.
Browse: all drugs starting with R · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4996 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1201832 — compound record and bioactivity
- PubChem CID 135449332 — chemical identifiers
- DrugBank DB05332 — drug record
- FDA UNII GN5XU2DXKV — substance identity
- DailyMed: FDA labels for Romiplostim — current prescribing information (label search)
- UniProt P40238 (MPL) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.